ArticleBMC cancer2025

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.

Omer Faruk Kuzu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.